PV Bulletin

Start of Procedure for Extension of Marketing Authorisation

The European Medicines Agency (EMA) has initiated a procedure for the extension of marketing authorisations for certain pharmaceutical products.

Primary source: EMA - What's new RSS

PV Impact Brief

Urgency: HighConfidence: low

What changed

A new reporting requirement has been introduced related to the extension of marketing authorisation for pharmaceutical products during the period from July 24, 2026 to August 20, 2026.

Why it matters

This change necessitates updated regulatory oversight and compliance workflows for pharmaceutical products seeking to extend their marketing authorisation.

Action needed

Regulatory Intelligence Leads must incorporate the new reporting requirements and deadlines into their monitoring activities for affected products.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Regulatory Intelligence Monitoring
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: lowSource updated: Aug 26, 2026

Primary-source confirmation recommended before operational implementation.

Full briefing

Practical implication

Regulatory Intelligence Leads must incorporate the new reporting requirements and deadlines into their monitoring activities for affected products.

A new reporting requirement for the extension of marketing authorisation has been established by the EMA, effective from July 24, 2026 to August 20, 2026.

What changed: A new reporting requirement has been introduced related to the extension of marketing authorisation for pharmaceutical products during the period from July 24, 2026 to August 20, 2026.

Why it matters: This change necessitates updated regulatory oversight and compliance workflows for pharmaceutical products seeking to extend their marketing authorisation.

Practical implication: Regulatory Intelligence Leads must incorporate the new reporting requirements and deadlines into their monitoring activities for affected products.

View original source

  • Source: EMA - What's new RSS
  • Published at source: 2026-08-26T00:00:00.000Z
  • Discovered by monitor: 2026-08-26T22:30:49.183Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Regulatory Intelligence#Reporting Requirement#Source-ingestion#Regulator-monitor#European Union#Ema.europa.eu

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Urgent Withdrawal of Reusable da Vinci S and Si Instruments Due to Cable Degradation

Urgency: High

Healthcare facilities must isolate the affected instruments and notify Intuitive Surgical for returns while preparing for potential delays in surgical procedures due to instrument replacements.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicANSM · France · Updated Sep 7, 2026Translated From French

Injunction No. 2026-DM-031-INJ Regarding Ortho Partner Establishment in Montreuil

Urgency: High

Establish compliant storage conditions for medical devices and set up a non-conformity management system within 3 months.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward